HC Wainwright Expects Lower Earnings for Abeona Therapeutics

Abeona Therapeutics Inc. (NASDAQ:ABEO) – Analysts at HC Wainwright decreased their Q1 2026 earnings estimates for shares of Abeona Therapeutics in a research note issued on Thursday, March 19th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings of ($0.32) per share for the quarter, down from their previous forecast of ($0.31). HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q2 2026 earnings at ($0.33) EPS, Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($1.14) EPS, Q1 2027 earnings at ($0.20) EPS, Q2 2027 earnings at ($0.16) EPS, Q3 2027 earnings at ($0.11) EPS, Q4 2027 earnings at $0.01 EPS and FY2027 earnings at ($0.47) EPS.

Abeona Therapeutics (NASDAQ:ABEO) last announced its earnings results on Tuesday, March 17th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.01. The firm had revenue of $3.00 million during the quarter, compared to analyst estimates of $5.65 million.

ABEO has been the topic of several other reports. Stifel Nicolaus set a $17.00 target price on Abeona Therapeutics in a research note on Tuesday, March 17th. Oppenheimer reiterated an “outperform” rating on shares of Abeona Therapeutics in a research note on Monday, March 9th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Abeona Therapeutics in a report on Wednesday, January 21st. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Abeona Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.00.

Abeona Therapeutics Stock Performance

Shares of ABEO stock opened at $4.45 on Monday. Abeona Therapeutics has a 12-month low of $3.93 and a 12-month high of $7.54. The business’s fifty day simple moving average is $5.07 and its 200-day simple moving average is $5.18. The company has a current ratio of 6.93, a quick ratio of 6.74 and a debt-to-equity ratio of 0.05. The company has a market cap of $253.87 million, a PE ratio of 4.32 and a beta of 1.13.

Insider Buying and Selling at Abeona Therapeutics

In related news, SVP Brendan M. O’malley sold 13,578 shares of the company’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $5.33, for a total value of $72,370.74. Following the transaction, the senior vice president directly owned 451,134 shares of the company’s stock, valued at $2,404,544.22. This represents a 2.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Christine Berni Silverstein sold 20,070 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $5.09, for a total value of $102,156.30. Following the completion of the transaction, the director owned 137,722 shares of the company’s stock, valued at $701,004.98. This trade represents a 12.72% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 209,605 shares of company stock valued at $1,101,300. Company insiders own 5.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ABEO. Boone Capital Management LLC purchased a new stake in Abeona Therapeutics in the second quarter valued at approximately $7,126,000. AWM Investment Company Inc. acquired a new position in Abeona Therapeutics in the 2nd quarter worth approximately $2,670,000. Squarepoint Ops LLC raised its position in Abeona Therapeutics by 274.2% during the 2nd quarter. Squarepoint Ops LLC now owns 141,978 shares of the biopharmaceutical company’s stock worth $806,000 after buying an additional 104,037 shares during the last quarter. Diametric Capital LP raised its position in Abeona Therapeutics by 637.8% during the 2nd quarter. Diametric Capital LP now owns 138,363 shares of the biopharmaceutical company’s stock worth $786,000 after buying an additional 119,609 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey acquired a new stake in Abeona Therapeutics during the 2nd quarter valued at approximately $63,000. 80.56% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Abeona Therapeutics

Here are the key news stories impacting Abeona Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $20.00 price target — a large upside vs. the current market price, which supports a bullish view if Abeona hits upcoming clinical or financial milestones. HC Wainwright Reiterates Buy
• Positive Sentiment: Analyst model shows potential recovery by 2027 (FY2027 EPS forecast of ($0.47) and a small positive EPS in Q4 2027), signaling HC Wainwright expects the company to narrow losses and approach profitability toward late 2027. MarketBeat ABEO
• Neutral Sentiment: HC Wainwright published a full set of quarter-by-quarter estimates through FY2027, providing a new baseline for investors to compare company results against. These estimates will be used as the reference for future beats/misses. MarketBeat ABEO
• Negative Sentiment: HC Wainwright trimmed several near‑term forecasts — including lowering FY2026 EPS to ($1.14) (from prior ~$0.97) and cutting Q1–Q3 2026 and Q4 2026 estimates — indicating higher expected losses in the near term and raising downside risk if revenue/cost trends don’t improve. MarketBeat ABEO
• Negative Sentiment: Multiple downward revisions to quarterly EPS for 2026 increase the odds of near‑term volatility around upcoming quarterly reports and any clinical updates. Expect the stock to be sensitive to any deviation from these lowered targets. MarketBeat ABEO

Abeona Therapeutics Company Profile

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.